Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01039025 · ClinicalTrials.gov registry record · Phase 2

TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target

NCT01039025: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT01039025 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01039025, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.

Interventions

  • DRUG Cyclophosphamide
  • DRUG Melphalan
  • DRUG Topotecan
  • OTHER Peripheral Blood Stem Cells

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2002-02-18
Est. Completion 2006-05-19
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT01039025 record still lists

NCT01039025 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.

NCT01039025 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01039025 about?

NCT01039025 is a clinical study titled "TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma". To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.

What is the current status of trial NCT01039025?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2002-02-18. Estimated completion is 2006-05-19.

What interventions are being tested in trial NCT01039025?

The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Topotecan (DRUG), Peripheral Blood Stem Cells (OTHER).

Who is sponsoring clinical trial NCT01039025?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT01039025's enrollment target sits among peer trials

60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01039025, the US trial registry maintained by the National Library of Medicine. NCT01039025 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.